Table 1.

Baseline characteristics of study participants (n = 172)

Baseline Variables	No. (%) or Mean (SD)	Correlation with Efficacy Expectancy (METE)	Correlation with Side Effect Expectancy (MESET)
Age, y	45·4 (15·4)	0·27***	−0·03
Gender (% Female)	115 (66·9%)	0·19*	−0·05
Race (% Caucasian)	129 (75·0%)	−0·09	−0·17*
Ethnicity (% Hispanic)	8 (4·7%)	0·09	−0·01
% Unemployed	31 (17·3%)	0·06	−0·18*
% Married	62 (34·6%)	0·01	−0·04
Age at first GAD episode	21.5 (15·4)	0·12	0.16*
Duration of current GAD episode (years)	8.4 (13·9)	−0·04	0·5
% Current major depressive episode	54 (31·4%)	0·07	0·02
Number of psychiatric co-morbidities	0·64 (0·84)	0·08	0·07
Number of previous psychopharmacological treatments for GAD	1·5 (1·7)	−0·03	0·02
GAD-7	15·1 (3·1)	0·01	0·07
HARS	14·7 (3·6)	−0·08	0·05
CGI-S	4·16 (0·38)	−0·13	−0·02
PGWB Total	54·4 (14·0)	0·07	−0·19*
METE	12·5 (3·5)	NA	−0·04
MESET	6·6 (2·7)	−0·04	NA

All reported correlations are Pearson correlations (for continuous variables), or point-biserial correlations coded such that positive values reflect the listed group having more of that expectancy (for categorical variables);

^*= p < ·05,

^***= p < ·001

CGI-S = Clinical Global Impression-State; GAD-7 = Generalized Anxiety Disorder 7-Item Scale; HARS = Hamilton Anxiety Rating Scale; METE = Mao Expectancy of Treatment Effects; MESET = Mao Expectancy of Side Effects of Treatment; PGWB = Psychological General Well Being